Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases

Purpose Although bevacizumab (BV) increases survival rates when used with chemotherapy (CTX) in patients who have metastatic colorectal cancer (CRC), an increase in wound complications has been observed in patients who undergo surgery while receiving BV. We therefore evaluated whether neoadjuvant BV...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Kesmodel, Susan (author)
مؤلفون آخرون:	Ellis, Lee (author), Lin, E. (author), Chang, George (author), Abdalla, Eddie (author), Kopetz, Scott (author), Vauthey, Jean-Nicolas (author), Rodriguez-Bigas, Miguel (author), Curley, Steven (author), Feig, Barry (author)
التنسيق:	article
منشور في:	2008
الوصول للمادة أونلاين:	http://hdl.handle.net/10725/2590 http://dx.doi.org/10.1200/JCO.2008.17.7857 http://jco.ascopubs.org/content/26/32/5254.short
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases

مواد مشابهة